원발성 고옥살산뇨증 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Primary Hyperoxaluria Market Outlook

Thelansis's "Primary Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Hyperoxaluria Overview

Primary hyperoxaluria is a rare inherited condition, most commonly its type 1 form, in which a malfunctioning liver enzyme causes the body to overproduce oxalate, leading to painful, recurrent kidney stones and progressive calcium oxalate deposits that can severely damage kidney function over time and, in advanced cases, spread beyond the kidneys to other organs. Historically, once kidney failure developed, treatment options were limited largely to combined liver and kidney transplantation, since replacing the liver was the only way to correct the underlying enzymatic defect driving oxalate overproduction. That changed with the arrival of RNA interference-based therapies designed to silence the specific liver enzymes responsible for oxalate production, offering a way to meaningfully lower oxalate levels without transplantation and marking one of the field's clearest examples of gene silencing technology translating into routine care, including in children. Two such therapies are now approved, each targeting a different point along the production pathway, giving physicians options depending on disease subtype and kidney function.

Key Highlights

• In Germany, diagnosed Primary Hyperoxaluria (PH) cases are projected to increase from 168 in 2025 to 171 by 2035.
• Primary Hyperoxaluria is a rare inherited metabolic disorder characterized by excessive oxalate production, leading to recurrent kidney stones and progressive renal damage.
• Delayed diagnosis can result in irreversible kidney dysfunction and systemic complications.
• Significant unmet need remains for therapies that prevent disease progression and preserve kidney function.

Market Overview

• The Spain Primary Hyperoxaluria market is projected to grow from $10M in 2025 to $22M by 2035.
• Market growth is driven by:
• Increasing adoption of RNA-targeted and disease-modifying therapies
• Improved genetic testing and earlier diagnosis
• Future growth will depend on therapies that effectively reduce oxalate production and improve long-term renal outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alnylam Pharmaceuticals
• YolTech Therapeutics Co., Ltd.
• Arbor Biotechnologies
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)